{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:39:11Z","timestamp":1786441151217,"version":"build-2736575974"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) ranks among the deadliest malignancies, with only 13% of patients surviving five years after diagnosis. This poor prognosis stems from late detection, treatment resistance, spatial and phenotypic heterogeneity, and a highly immunosuppressive tumor microenvironment. Unlike immunogenic cancers, PDAC is an immunologically \u2018cold\u2019 tumor, marked by minimal immune cell infiltration, defective antigen-presentation machinery, and stromal barriers. While immune checkpoint blockade (ICB) has shown success against various cancers, it has proven largely ineffective when used alone in PDAC. However, emerging research has identified promising new approaches, including neoantigen-targeted vaccines, stromal modulation, and combination therapies such as ICB with chemotherapy, cytokine blockade, and kinase inhibitors. The development of personalized immunotherapy approaches is being refined by predictive biomarkers that assess factors such as T cell infiltration levels, antigen-presenting capacity, and the spatial immune cell landscape. Here, we review the immune landscape of PDAC, current and emerging immunotherapeutic strategies, and highlight the critical role of biomarkers and immune profiling in appropriately categorizing patients. Collectively, these insights provide a foundation for designing rational combination therapies to transform PDAC into a cancer that is more immunologically responsive and amenable to therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1909191","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:19:56Z","timestamp":1786439996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking PDAC: from immunological silence to therapeutic opportunity"],"prefix":"10.3389","volume":"17","author":[{"given":"Suresh K.","family":"Kali","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remya P. G.","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aftab","family":"Alam","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Fernandez-Cabezudo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, College of Medicine and Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]},{"name":"Zayed Center for Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aydah M.","family":"Al-Awadhi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Sheikh Shakhbout Medical City","place":["Abu Dhabi, United Arab Emirates"]},{"name":"Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Kishore","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medicine, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]},{"name":"Zayed Center for Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel K.","family":"Al-Ramadi","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]},{"name":"Zayed Center for Health Sciences, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]},{"name":"ASPIRE Precision Medicine Research Institute Abu Dhabi, United Arab Emirates University","place":["Al Ain, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573522","article-title":"Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma","volume":"16","author":"Ramesh","year":"2025","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0109-y","article-title":"Molecular subtypes of pancreatic cancer","volume":"16","author":"Collisson","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1323198","article-title":"Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma","volume":"15","author":"Joseph","year":"2024","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/jci191945","article-title":"Experimental models of pancreas cancer: what has been the impact for precision medicine","volume":"135","author":"Pantazopoulou","year":"2025","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1569884","article-title":"Immune checkpoint inhibitors in pancreatic adenocarcinoma: a systematic review and meta analysis of clinical outcomes","volume":"15","author":"Al-Khinji","year":"2025","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01170-9","article-title":"Pancreatic cancer: advances in immunology, translational analyses and therapeutic paradigms","volume":"23","author":"O'Reilly","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/s41467-024-55424-2","article-title":"Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms","volume":"16","author":"Sivakumar","year":"2025","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1181538","article-title":"High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma","volume":"14","author":"Pan","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3141","article-title":"Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer","volume":"27","author":"V\u00e4yrynen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41392-020-00341-1","article-title":"Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer","volume":"5","author":"Bulle","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.751311","article-title":"The PDAC extracellular matrix: a review of the ECM protein composition, tumor cell interaction, and therapeutic strategies","volume":"11","author":"Perez","year":"2021","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1053\/j.gastro.2018.05.051","article-title":"NF\u03baB in pancreatic stellate cells reduces infiltration of tumors by cytotoxic T cells and killing of cancer cells, via up-regulation of CXCL12","volume":"155","author":"Garg","year":"2018","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/s41467-023-40850-5","article-title":"Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors","volume":"14","author":"Xiao","year":"2023","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155006","article-title":"Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner","volume":"8","author":"Ware","year":"2023","journal-title":"JCI Insight"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71637","article-title":"Efficacy and safety of combination therapy with immune checkpoint inhibitors and chemotherapy with gemcitabine and nab-paclitaxel in pancreatic cancer: a systematic review","volume":"15","author":"Sohrabi","year":"2026","journal-title":"Cancer Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12029-025-01194-z","article-title":"Immune-based therapies in pancreatic cancer: a systematic review of ongoing clinical trials (2020-2022)","volume":"56","author":"Hung","year":"2025","journal-title":"J Gastrointestinal Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02389-7","article-title":"Transcription factor switching drives subtype-specific pancreatic cancer","volume":"57","author":"Rao","year":"2025","journal-title":"Nat Genet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00121-4","article-title":"Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer","volume":"1","author":"Steele","year":"2020","journal-title":"Nat Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3753","article-title":"Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis","volume":"49","author":"McDonald","year":"2017","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.cell.2017.07.007","article-title":"Enhancer reprogramming promotes pancreatic cancer metastasis","volume":"170","author":"Roe","year":"2017","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-025-05368-y","article-title":"Deciphering the enigma: long noncoding RNAs in disease pathogenesis and therapeutic prospects","volume":"480","author":"Ramesh","year":"2025","journal-title":"Mol Cell Biochem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00553-8","article-title":"EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance","volume":"4","author":"Chibaya","year":"2023","journal-title":"Nat Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00258-w","article-title":"TNF-\u03b1-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer","volume":"2","author":"Tu","year":"2021","journal-title":"Nat Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ccell.2018.02.003","article-title":"Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors","volume":"33","author":"Andricovich","year":"2018","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","first-page":"100939","DOI":"10.1016\/j.ctarc.2025.100939","article-title":"Molecular analysis highlights TREM2 as a discriminating biomarker for patients suffering from pancreatic ductal adenocarcinoma","volume":"43","author":"Papakonstantinou","year":"2025","journal-title":"Cancer Treat Res Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s12026-025-09666-x","article-title":"SPP1\u2009+\u2009macrophages facilitate pancreatic cancer progression via ITGB6-mediated interactions: evidence from integrated multi-omics analysis and experimental validation","volume":"73","author":"Ge","year":"2025","journal-title":"Immunol Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41698-026-01293-5","article-title":"Identification and characterization of MARCO-expressing tumor-associated macrophages in pancreatic ductal adenocarcinoma with pan-cancer relevance","volume":"10","author":"Sun","year":"2026","journal-title":"NPJ Precis Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13059-020-02222-w","article-title":"Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma","volume":"22","author":"Yang","year":"2021","journal-title":"Genome Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i46.7956","article-title":"T cells in pancreatic cancer stroma","volume":"27","author":"Goulart","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.363","article-title":"A signature of 18 immune-related gene pairs to predict the prognosis of pancreatic cancer patients","volume":"8","author":"Bu","year":"2020","journal-title":"Immun Inflammation Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"13431","DOI":"10.1038\/s41598-025-98503-0","article-title":"Establishment and validation of an immune-related nomogram for the prognosis of pancreatic adenocarcinoma","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-0525","article-title":"Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2\/CCR2 axis","volume":"19","author":"Sanford","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2024.11.016","article-title":"CXCL1-CXCR2 signaling mediates the activation of microglia in the nucleus tractus solitarii to promote pancreatic cancer-induced pain","volume":"123","author":"Chen","year":"2025","journal-title":"Brain Behav Immun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13107","article-title":"IL-6 is associated with expansion of myeloid-derived suppressor cells and enhanced immunosuppression in pancreatic adenocarcinoma patients","volume":"94","author":"Sharma","year":"2021","journal-title":"Scand J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13046-024-03178-6","article-title":"Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma","volume":"43","author":"Luo","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-25-0575","article-title":"Nonredundant immune checkpoints direct therapeutic resistance to chemoimmunotherapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Stone","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0061","article-title":"A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-1660","article-title":"Facts and hopes of CD40 agonists in cancer immunotherapy","volume":"31","author":"McVey","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.195329","article-title":"TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma","volume":"11","author":"Plesset","year":"2026","journal-title":"JCI Insight"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0876","article-title":"Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer","volume":"13","author":"Falcomat\u00e0","year":"2023","journal-title":"Cancer Discov"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1155085","article-title":"The tumor stroma influences immune cell distribution and recruitment in a PDAC-on-a-chip model","volume":"14","author":"Geyer","year":"2023","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-23-2352","article-title":"Multiplexed imaging mass cytometry analysis characterizes the vascular niche in pancreatic cancer","volume":"84","author":"Sussman","year":"2024","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-25-1697","article-title":"High-dimensional protein analysis uncovers distinct immunologic and stromal features in primary and metastatic pancreatic ductal adenocarcinoma","volume":"86","author":"Greene","year":"2026","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16060","article-title":"Immature stroma and high infiltration of CD15+ cells are predictive markers of poor prognosis in different subsets of patients with pancreatic cancer","volume":"115","author":"Yamada","year":"2024","journal-title":"Cancer Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.3390\/ijms21114067","article-title":"From Malignant progression to therapeutic targeting: Current insights of mesothelin in pancreatic ductal adenocarcinoma","volume":"21","author":"Montemagno","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk3487","article-title":"Pancreatic cancer\u2013restricted cryptic antigens are targets for T cell recognition","volume":"388","author":"Ely","year":"2025","journal-title":"Science"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/s41467-026-68324-4","article-title":"Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial","volume":"17","author":"Huff","year":"2026","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.3390\/cells11193175","article-title":"KRAS G12D mutation subtype in pancreatic ductal adenocarcinoma: Does it influence prognosis or stage of disease at presentation","volume":"11","author":"Shen","year":"2022","journal-title":"Cells"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1571182","article-title":"Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study","volume":"16","author":"Oyama","year":"2025","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12885-019-5630-4","article-title":"Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study","volume":"19","author":"Gbolahan","year":"2019","journal-title":"BMC Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03289.x","article-title":"Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines","volume":"148","author":"Pandha","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pan.2023.04.030","article-title":"FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer","volume":"73","author":"Canel","year":"2024","journal-title":"Gut"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1038\/s41467-019-12657-w","article-title":"The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"Michaelis","year":"2019","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"B69","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS626","article-title":"Phase Ib\/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer","volume-title":"J Clin Oncol","author":"Akce","year":"2022"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"key":"B71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS713","article-title":"A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC)","volume-title":"J Clin Oncol","author":"Hosein","year":"2024"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14640","article-title":"A patient with locally advanced mismatch-repair-deficient pancreatic ductal adenocarcinoma successfully treated with neoadjuvant immunotherapy","volume":"13","author":"Cox","year":"2021","journal-title":"Cureus"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-4070","article-title":"FDA approval summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1659656","article-title":"Case report: immunotherapy response in pancreatic cancer after MSI-H emerged post-chemotherapy","volume":"16","author":"Gharaybeh","year":"2026","journal-title":"Front Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1158\/1078-0432.ccr-19-2803","article-title":"A four-chemokine signature is associated with a T-cell\u2013inflamed phenotype in primary and metastatic pancreatic cancer","volume":"26","author":"Romero","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10038","article-title":"Prognostic value, localization and correlation of PD-1\/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma","volume":"7","author":"Diana","year":"2016","journal-title":"Oncotarget"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1172\/jci91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860767","article-title":"Intra-tumoral CD8+ T-cell infiltration and PD-L1 positivity in homologous recombination deficient pancreatic ductal adenocarcinoma","volume":"12","author":"Golesworthy","year":"2022","journal-title":"Front Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-24-0299","article-title":"Tertiary lymphoid structures in pancreatic cancer are structurally homologous, share gene expression patterns and B-cell clones with secondary lymphoid organs, but show increased T-cell activation","volume":"13","author":"Lehmann","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08426-5","article-title":"IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer","volume":"638","author":"Amisaki","year":"2025","journal-title":"Nature"},{"key":"B84","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2026.05.005","article-title":"A multi-subunit autophagic capture complex facilitates degradation of ER stalled MHC-I in pancreatic cancer","volume-title":"Mol Cell","author":"Berquez","year":"2026"},{"key":"B85","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-024-03060-5","article-title":"Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells","volume":"43","author":"Zhong","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010908","article-title":"B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC","volume":"13","author":"Xing","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"7041","DOI":"10.1038\/s41467-021-27349-7","article-title":"Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance","volume":"12","author":"Deng","year":"2021","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12943-025-02513-5","article-title":"Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy","volume":"24","author":"Zheng","year":"2025","journal-title":"Mol Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000003986","article-title":"Microbiota in pancreatic ductal adenocarcinoma progression and therapy: The hidden players","volume":"139","author":"Hu","year":"2026","journal-title":"Chin Med J (Engl)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor microbiome diversity and composition influence pancreatic cancer outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.785422","article-title":"Intratumor microbiome analysis identifies positive association between Megasphaera and survival of Chinese patients with pancreatic ductal adenocarcinomas","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-1134","article-title":"The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression","volume":"8","author":"Pushalkar","year":"2018","journal-title":"Cancer Discov"},{"key":"B94","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12029-025-01368-9","article-title":"Synergistic effect of fecal microbiota transplantation, \u03b3\u03b4T cell immunotherapy, and pembrolizumab in refractory advanced pancreatic cancer: a case report","volume":"57","author":"Alnaggar","year":"2026","journal-title":"J Gastrointest Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/nmat4997","article-title":"Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma","volume":"16","author":"Xu","year":"2017","journal-title":"Nat Mater"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.31373","article-title":"Circulating tumor DNA and tissue testing for pancreatobiliary tumors","volume":"8","author":"Mahadevia","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1745466","article-title":"Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer","volume":"16","author":"Chen","year":"2026","journal-title":"Front Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1200\/cci.21.00124","article-title":"Intron-retention neoantigen load predicts favorable prognosis in pancreatic cancer","volume":"6","author":"Dong","year":"2022","journal-title":"JCO Clin Cancer Inform"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"\u0141uksza","year":"2022","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"B102","doi-asserted-by":"publisher","first-page":"12175","DOI":"10.1038\/s41598-025-97233-7","article-title":"Evaluation of the efficacy and predictive indicators of PD- 1 inhibitors combined with chemotherapy in advanced pancreatic cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"B103","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","article-title":"Phase Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma","volume":"36","author":"Weiss","year":"2018","journal-title":"Invest New Drugs"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1159\/000500571","article-title":"A phase 1b\/2 study of the bruton tyrosine kinase inhibitor ibrutinib and the PD-L1 inhibitor durvalumab in patients with pretreated solid tumors","volume":"97","author":"Hong","year":"2019","journal-title":"Oncology"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther"},{"key":"B108","article-title":"A phase I study of autologous CAR-T cells targeting the B7-H3 antigen and containing the inducible caspase 9 safety switch in subjects with refractory pancreatic ductal adenocarcinoma (PDAC). Rep. NCT06158139","year":"2025","journal-title":"clinicaltrialsgov"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04043-5","article-title":"Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1\/2 trial","volume":"32","author":"Musher","year":"2026","journal-title":"Nat Med"},{"key":"B110","article-title":"A Phase 1\/2, Open-label, Biomarker-guided, Dose-escalation and Expansion Study of Dual-targeting CAR-NK Cells Directed Against Mesothelin (MSLN) and MUC1, With an Exploratory CLDN18.2\/MUC1 Dual-target Cohort, in Patients With Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Rep. NCT07627711. clinicaltrialsgov","year":"2026"},{"key":"B111","article-title":"Open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-175 in human leukocyte antigen-a*02:01-positive adult subjects with unresectable, advanced and\/or metastatic solid tumors that are positive for the TP53 R175H mutation","volume-title":"J Clin Oncol","author":"Awad","year":"2024"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201069","article-title":"Oncolytic viruses: A novel therapeutic approach for pancreatic cancer","volume":"33","author":"Esteves","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2833","article-title":"2216MO VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with\/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)","volume":"36","author":"Garcia-Carbonero","year":"2025","journal-title":"Ann Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04299-5","article-title":"Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial","volume":"32","author":"Park","year":"2026","journal-title":"Nat Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"589","DOI":"10.20944\/preprints202412.2086.v1","article-title":"Advancing immunotherapy in pancreatic cancer: A brief review of emerging adoptive cell therapies","volume":"17","author":"Sherpally","year":"2025","journal-title":"Cancers"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2025.11.061","article-title":"A systems biology approach to unveil shared therapeutic targets and pathological pathways across major human cancers","volume":"27","author":"Alam","year":"2025","journal-title":"Comput Struct Biotechnol J"},{"key":"B117","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41540-026-00698-z","article-title":"Targeting protein protein interactions and their modulators to enable new therapeutic strategies for human diseases","volume":"12","author":"Alam","year":"2026","journal-title":"NPJ Syst Biol Appl"},{"key":"B118","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/nejmoa2208470","article-title":"Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"13189","DOI":"10.1038\/s41598-026-40757-3","article-title":"Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer","volume":"16","author":"Tiede","year":"2026","journal-title":"Sci Rep"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0489","article-title":"Combined KRAS inhibition and immune therapy generates durable complete responses in an autochthonous PDAC model","volume":"15","author":"Liu","year":"2025","journal-title":"Cancer Discov"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2024.03.009","article-title":"Dendritic cell-based immunotherapy in patients with resected pancreatic cancer","volume":"42","author":"van 't Land","year":"2024","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le Dung","year":"2015","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-3401","article-title":"Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic\/predictive significance","volume":"24","author":"Wartenberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1158\/1078-0432.ccr-19-2803","article-title":"A four-chemokine signature is associated with a T-cell-inflamed phenotype in primary and metastatic pancreatic cancer","volume":"26","author":"Romero","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03070","article-title":"Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma","volume":"10","author":"Siret","year":"2019","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add1834","article-title":"The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers","volume":"16","author":"Voissi\u00e8re","year":"2024","journal-title":"Sci Transl Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-2025-283","article-title":"Peripheral blood neutrophil-to-lymphocyte ratio as a prognostic marker and its association with the tumor-immune microenvironment in pancreatic cancer: a retrospective cohort study","volume":"16","author":"Li","year":"2025","journal-title":"J Gastrointest Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13383-w","article-title":"Sintilimab plus modified FOLFIRINOX in metastatic or recurrent pancreatic cancer: the randomized phase II CISPD3 trial","volume":"30","author":"Fu","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B131","article-title":"First in human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with kirsten rat sarcoma (KRAS) mutated pancreatic ductal adenocarcinoma and other solid tumors. Rep. NCT04853017","author":"Elicio","year":"2025","journal-title":"clinicaltrialsgov"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-0499","article-title":"A Phase Ib\/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma","volume":"30","author":"Coveler","year":"2024","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153902","article-title":"Irreversible electroporation and nivolumab combined with intratumoral administration of a toll-like receptor ligand, as a means of in vivo vaccination for metastatic pancreatic ductal adenocarcinoma (PANFIRE-III). A phase-I study protocol","volume":"13","author":"Geboers","year":"2021","journal-title":"Cancers"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk1827","article-title":"Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells","volume":"10","author":"Wang","year":"2024","journal-title":"Sci Adv"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02585","article-title":"Dendritic cell\u2013based immunotherapy in patients with resected pancreatic cancer","volume":"42","author":"van \u2018t Land","year":"2024","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-sitc2022.0708","article-title":"708 MEDI1191 (IL-12 mRNA) induces peripheral and intratumoral immunostimulatory effect in patients with cutaneous or subcutaneous (C\/SC) lesions","volume":"10","author":"Abadier","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B137","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","article-title":"A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer","volume":"18","author":"Hirooka","year":"2018","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1909191\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:19:58Z","timestamp":1786439998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1909191\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":137,"alternative-id":["10.3389\/fimmu.2026.1909191"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1909191","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1909191"}}